PathAI logo
Poster

Artificial intelligence–powered immune phenotyping of advanced or metastatic urothelial carcinoma clinical trial samples from hematoxylin and eosin–stained whole slide images

SITC 2022

Study Background


  • First-line (1L) maintenance with avelumab, an anti–PD-L1 antibody, combined with best supportive care (BSC) significantly prolonged overall survival vs BSC alone in the JAVELIN Bladder 100 clinical trial enrolling patients with advanced or metastatic UC that had not progressed with 1L platinum-containing chemotherapy1,2

  • Results from this trial led to the approval of avelumab 1L maintenance in various countries worldwide, and the JAVELIN Bladder regimen is an established standard of care in international treatment guidelines based on level 1 evidence3-8

  • PathAI machine learning (ML) models have previously been deployed to characterize the tumor microenvironment in a range of cancer types9


References:
1. Powles T, et al. N Engl J Med. 2020;383(13):1218-30.
2. Powles T, et al. J Clin Oncol. 2022;40(Suppl 6). Abstract 487.
3. Bavencio (avelumab). Prescribing information. EMD Serono; 2022.
4. Bavencio (avelumab). Summary of product characteristics. Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck KGaA, Darmstadt, Germany; 2022.
5. NCCN Clinical Practice Guidelines. Bladder Cancer. V1.2022.
6. Powles T, et al. Ann Oncol. 2022;33(3):244-58.
7. Cathomas R, et al. Eur Urol. 2022;81(1):95-103.
8. Japanese Urological Association. Accessed September 15, 2022. https://www.urol.or.jp/lib/files/other/guideline/39_bladder_cancer_2019_rev2021_info.pdf.
9. Diao J, et al. Nat Comms. 2021;12:1613.
View Poster

Authors

Conway et al.